Medtronic nudges profit forecast on medical devices demand, new launches
Adds shares in paragraph 1, company comments from conference call in paragraphs 7,8, 10 and 13, analyst comment in paragraph 11, graphic
By Sriparna Roy and Puyaan Singh
Aug 20 (Reuters) -Medtronic MDT.N slightly lifted the lower end of its annual profit forecast on Tuesday, banking on sustained demand for its medical devices and growth from its newlaunches, sending its shares up 1.6%.
Investor expectations from medical device makers remain high as they have beenbenefiting from elevated demand for non-urgent surgeries over the last few quarters.
The company said it was expecting steady growth as it introduces new products and continues to make investments to support those launches.
Earlier this month, the company won the U.S. health regulator's nod for its disposable, all-in-one continuous glucose monitor (CGM), Simplera.
It also announced a partnership under which Abbott's ABT.N CGM system will connect to Medtronic's automated insulin delivery systems.
The Ireland-based company also eyes growth across segments such as diabetes and devices for heart disease-focused surgeries.
Medtronic also remains "on the hunt" for the right tuck-in deals. "I don't want to point out specific areas other than the high growth areas - whether they be a product, tuck into an existing business ... That's where we're focused," said CEO Geoff Martha on a conference call.
The company raised the lower end of its 2025 adjusted profit forecast to$5.42 per share from $5.40 apiece earlier, keeping the upper end at $5.50. Analysts, on average, were expecting profit of $5.44 for 2025, according to LSEG data.
It expects profit growth to accelerate in the back half of the year as the impact from foreign currency lessens.
The delivery, particularly pockets of strength, and the raised outlook was a nice surprise, said Citi analyst Joanne Wuensch.
The company posted a revenue beat across segments except for its medical surgical unit, which was affected by a slowdown in the Korean market due to theongoing physician strikes.
Medtronic posted adjusted profit of $1.23 per share for the first quarter, beating estimates of $1.20.
Medtronic's revenue by segment https://reut.rs/4csdg8Q
Reporting by Sriparna Roy and Puyaan Singh in Bengaluru; Editing by Sriraj Kalluvila, Devika Syamnath and Alan Barona
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
